ICML 2019 | Rituximab maintenance shows no advantage over observation in DLBCL

Pieternella Lugtenburg

Pieternella Lugtenburg, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the results from a randomized Phase III study of rixtuximab maintenance for patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (HOVON 84 NHL; NTR1014). For this study population, maintenance therapy with rituximab displayed no advantage compared with observation alone. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video